Send us Fan Mail

Episode 4: Faster Hypernatremia Correction & Long-Acting Antibiotics for Staph Bacteremia

With Special Guest Dr. Kevin Baker

In this episode of Inpatient Update, Dr. Mason Turner is joined by hospitalist Dr. Kevin Baker to discuss two studies that challenge long-held dogma in inpatient medicine:

• Faster correction of hypernatremia — is the traditional “go slow” rule actually harming patients?
• Dalbavancin for Staph aureus bacteremia (DOTS Trial) — can two long-acting antibiotic injections replace weeks of IV therapy and PICC lines?

Practical take-homes, real-world discussion, and what to change on rounds tomorrow (with a couple of bourbons).

Articles & PubMed Links

Clinical outcomes of early fast compared to slow sodium correction rate in adults with severe hypernatremia: A comparative effectiveness study

Journal of Critical Care (2025)

Key Findings

• Faster correction associated with lower 30-day mortality
• Shorter ICU length of stay
• Shorter hospital length of stay
• No signal for neurologic complications from rapid correction

Supporting data from prior studies:

• 2023 JAMA observational cohort
  Faster correction associated with lower mortality
  No neurologic complications reported
• 2025 Journal of Critical Care meta-analysis
  Faster correction not associated with worse outcomes

Takeaway

For adult hypernatremia, especially in critically ill patients, more aggressive correction appears safe and may improve outcomes.

Pubmed: https://pubmed.ncbi.nlm.nih.gov/41240509/

Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial

JAMA 2025

Compared:

Standard Therapy

• 4–8 weeks IV antibiotics
• Cefazolin / anti-staphylococcal penicillin (MSSA)
• Vancomycin or daptomycin (MRSA)

vs

Dalbavancin Strategy

• 1500 mg IV day 1
• 1500 mg IV day 8

Long-acting lipoglycopeptide with ~14-day half-life, allowing completion of therapy without PICC lines.

Population

• Complicated Staph aureus bacteremia

Key Results

Clinical efficacy:

• Dalbavancin: 73%
• Standard therapy: 72%

Microbiologic success:

• Dalbavancin: 98.8%
• Standard therapy: 96.3%

Met criteria for non-inferiority.

Takeaway

For selected patients with cleared Staph aureus bacteremia, two doses of dalbavancin may replace weeks of IV antibiotics and PICC lines.

Potential advantages:

• Avoids central line complications
• Simplifies discharge planning
• Useful in patients with difficult social situations or IV access concerns

Pubmed: https://pubmed.ncbi.nlm.nih.gov/40802264/

Practice-Changing Takeaways

• Hypernatremia: Faster correction appears safe in adults and IMPROVES mortality.
• Staph bacteremia: Long-acting dalbavancin offers a PICC-free alternative for completing therapy in selected patients.
• Hospital medicine continues to move toward shorter and simpler antibiotic strategies.